Crescita Therpeutc (CTX) Price & Analysis

Compare

13 Followers

CTX Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$0.45 - C$0.70

Previous CloseN/A

Volume9.50K

Average Volume (3M)12.21K

Market Cap

C$9.19M

Enterprise ValueC$1.37M

Total Cash (Recent Filing)C$8.54M

Total Debt (Recent Filing)C$718.00K

Price to Earnings (P/E)―

Beta0.19

Next Earnings

Aug 06, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding18,939,262

10 Day Avg. Volume9,441

30 Day Avg. Volume12,207

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)0.62

Price to Sales (P/S)0.00

P/FCF Ratio-27.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$0.50

Price Target Upside4.17% Upside

Rating ConsensusHold

Number of Analyst Covering1

Crescita Therpeutc News

PremiumCompany Announcements

Crescita Therapeutics Reports Positive Shareholder Meeting Outcomes

1M ago

PremiumCompany Announcements

Crescita Therapeutics Regains Pliaglis Rights After Ending Croma Agreement

2M ago

PremiumCompany Announcements

Crescita Therapeutics Reports Decline in Q1 2025 Financial Results

2M ago

PremiumCompany Announcements

Crescita Therapeutics Reports 2024 Financial Results and Strategic Developments

4M ago

PremiumCompany Announcements

Crescita Therapeutics Sees Strong Q3 Revenue Growth

8M ago

CTX

PremiumCompany Announcements

Crescita Therapeutics Positions for Growth Amid Q2 Challenges

11M ago

CTX

PremiumCompany Announcements

Crescita Therapeutics Secures Lucrative Manufacturing Deal

12M ago

CTX

PremiumCompany Announcements

Crescita Secures Exclusive Manufacturing Deal in Healthcare

12M ago

CTX

See All TSE:CTX News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

1.77% Insiders

―

Mutual Funds

― Other Institutional Investors

98.23% Public Companies and

Individual Investors

Detailed Ownership Overview >

CTX FAQ

What was Crescita Therpeutc’s price range in the past 12 months?

Crescita Therpeutc lowest stock price was C$0.45 and its highest was C$0.70 in the past 12 months.

What is Crescita Therpeutc’s market cap?

Crescita Therpeutc’s market cap is C$9.19M.

When is Crescita Therpeutc’s upcoming earnings report date?

Crescita Therpeutc’s upcoming earnings report date is Aug 06, 2025 which is in 26 days.

How were Crescita Therpeutc’s earnings last quarter?

Crescita Therpeutc released its earnings results on May 14, 2025. The company reported -C$0.049 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.049.

Is Crescita Therpeutc overvalued?

According to Wall Street analysts Crescita Therpeutc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Crescita Therpeutc pay dividends?

Crescita Therpeutc does not currently pay dividends.

What is Crescita Therpeutc’s EPS estimate?

Crescita Therpeutc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Crescita Therpeutc have?

Crescita Therpeutc has 18,939,262 shares outstanding.

What happened to Crescita Therpeutc’s price movement after its last earnings report?

Crescita Therpeutc reported an EPS of -C$0.049 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.887%.

Which hedge fund is a major shareholder of Crescita Therpeutc?

Currently, no hedge funds are holding shares in TSE:CTX

Company Description

Crescita Therpeutc

Crescita Therapeutics Inc. (CTX) is a Canadian commercial dermatology company that operates in the pharmaceutical and healthcare sectors. The company is focused on the development and commercialization of topical dermatology treatments, offering a range of prescription and over-the-counter skin care products. Crescita Therapeutics leverages its patented transdermal delivery technologies to enhance the efficacy and safety of its dermatological solutions.

CTX Stock 12 Month Forecast

Average Price Target

C$0.50

▲(4.17%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","1":"C$1","-1":"-C$1","-0.5":"-C$0.5","0.5":"C$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.52,0.5184615384615385,0.5169230769230769,0.5153846153846154,0.5138461538461538,0.5123076923076924,0.5107692307692308,0.5092307692307693,0.5076923076923077,0.5061538461538462,0.5046153846153846,0.5030769230769231,0.5015384615384615,{"y":0.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.52,0.5184615384615385,0.5169230769230769,0.5153846153846154,0.5138461538461538,0.5123076923076924,0.5107692307692308,0.5092307692307693,0.5076923076923077,0.5061538461538462,0.5046153846153846,0.5030769230769231,0.5015384615384615,{"y":0.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.52,0.5184615384615385,0.5169230769230769,0.5153846153846154,0.5138461538461538,0.5123076923076924,0.5107692307692308,0.5092307692307693,0.5076923076923077,0.5061538461538462,0.5046153846153846,0.5030769230769231,0.5015384615384615,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.52,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.66,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.66,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.6,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.58,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.55,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.58,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.57,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.56,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.58,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.58,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.52,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.52,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >